Belantamab Mafodotin: First Approval
Autor: | Anthony Markham |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Immunoconjugates medicine.drug_class Antibodies Monoclonal Humanized Monoclonal antibody 03 medical and health sciences 0302 clinical medicine Antigen Cell Line Tumor medicine Animals Humans Cytotoxic T cell Pharmacology (medical) B-Cell Maturation Antigen Infusions Intravenous Drug Approval Multiple myeloma Neoplasm Staging Clinical Trials as Topic biology business.industry medicine.disease Xenograft Model Antitumor Assays Progression-Free Survival Tubulin Modulators Monomethyl auristatin F Drug Resistance Neoplasm 030220 oncology & carcinogenesis Monoclonal Disease Progression biology.protein Cancer research Proteasome inhibitor Neoplasm Recurrence Local Antibody Multiple Myeloma business Oligopeptides 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Drugs. 80:1607-1613 |
ISSN: | 1179-1950 0012-6667 |
DOI: | 10.1007/s40265-020-01404-x |
Popis: | Belantamab mafodotin (BLENREP™; belantamab mafodotin-blmf) is a first-in-class monoclonal antibody-drug conjugate (ADC) that has been developed for the treatment of multiple myeloma by GlaxoSmithKline. The ADC comprises an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). The antibody moiety binds to BCMA on the tumour cell surface, delivering the cytotoxic microtubule inhibitor MMAF to the therapeutic target. Based on preliminary results from the multinational DREAMM-2 trial, belantamab mafodotin was approved in early August 2020 in the USA for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including an anti CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The ADC was also approved in the EU for this indication in late August 2020. This article summarizes the milestones in the development of belantamab mafodotin leading to this first approval. |
Databáze: | OpenAIRE |
Externí odkaz: |